The DOI matches its Crossref record.
The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss
Abstract
The present authors report a 2-year study of estrogen therapy for the prevention or reduction of postmenopausal bone loss. The aim of the investigation was to determine the minimum effective dose of estrogen for postmenopausal and oophorectomized women. Of the 150 patients enrolled in the study, 108 completed 2 years of therapy. Thirty patients were allocated to each of four dose levels of conjugated equine estrogens: 1.25, 0.625, 0.3, and 0.15 mg per day. All patients were allocated randomly to a dose level and were compared with 30 patients randomly given nonmatching placebo tablets (Table 1). The mean heights and weights of the groups were comparable and did not change significantly throughout the study. Total serum calcium (corrected for changes in serum albumin) and phosphate were significantly reduced by 0.625 and by 1.25 mg of conjugated estrogens per day but not by any of the lower doses. In the measurements taken before treatment, serum calcium was significantly higher in the group given 0.625 mg per day than in all other groups. Serum phosphate also was higher in the 0.625-mg and 1.25-mg groups before therapy. The reasons for these differences are obscure, but the finding does not interfere with the interpretation of the results. In conjunction with the changes in serum levels, urinary calcium was reduced only in those groups given 0.625 and 1.25 mg of estrogen per day. In the pretreatment measurements, urinary calcium was somewhat reduced in the group given 0.625 mg per day, as compared with other groups. This is perhaps compatible with the slightly higher level of serum calcium. Despite this lower starting point, 0.625 mg of conjugated equine estrogens per day reduces urinary calcium significantly. Urinary hydroxyproline also was significantly reduced at 0.625 and 1.25 mg per day but not at the lower dose levels. Bone mineral content, estimated by single photon absorptiometry, fell significantly in the placebo (0.15− and 0.3− mg-treated) groups, with no significant difference in behavior between groups. Conjugated equine estrogens at 0.625 and 1.25 mg per day afforded significant protection against bone loss. Construction of a dose-response curve suggested that a 50 per cent response rate would be obtained at 0.45 mg of estrogens per day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Design of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Hormone therapy for preventing cardiovascular disease in post-menopausal women
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub4 · Cited by 612
Postmenopausal Bone Loss Is Prevented by Treatment with Low-Dosage Estrogen with Calcium
ETTINGER, B., GENANT, H. K., & CANN, C. E. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-1-40 · Cited by 531
Hormonal Treatment of Postmenopausal Women
Wood, A. J. J., & Belchetz, P. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301508 · Cited by 384
Metadata
- Authors
- LINDSAY, R., HART, D. M., & CLARK, D. M.
- Venue
- Obstetrical & Gynecological Survey
- Published
- 1985-02
- Volume
- 40
- Issue
- 2
- Pages
- 96-97
- ISSN
- 0029-7828 (ISSN-L)
- OpenAlex
- W44375275
- Cited by
- 393
- References
- 0
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss. https://app.cochat.ai/papers/10.1097/00006254-198502000-00016
- The paper
- LINDSAY, R., HART, D. M., & CLARK, D. M. (1985). The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss. Obstetrical & Gynecological Survey. https://doi.org/10.1097/00006254-198502000-00016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.